This additional funding comes at the heels of Selux announcing their third FDA 510(k) clearance on their direct from Positive Blood Culture Separator, making them the only single-platform technology capable of delivering rapid AST results for both positive blood culture and isolated colonies.

The Selux PBC Separator, part of the Next Generation Phenotyping (NGP) System, makes this the only FDA cleared, single-platform technology capable of delivering rapid AST results for both positive blood culture and isolated colonies.

Approval gives way to the most comprehensive single menu offered by an AST platform while delivering precise, rapid results in 5.5 hours from isolated colonies.

Former President of BD North America brings global healthcare leadership experience as Selux launches its recently FDA-cleared NGP System for rapid antibiotic susceptibility testing.

In vitro antimicrobial resistance test enables clinical labs to deliver targeted therapeutic results days faster than the current standard of care, clearing the path for personalized antibiotic therapies